The findings from an assessment of the feasibility and potential impact of delivering antiretroviral (ARV)-based oral and injectable pre-exposure prophylaxis (PrEP) and vaginal microbicide gels in South Africa are summarized in this brief. Conducted from December 1, 2010, to December 31, 2012, the study was designed to: 1) identify the most feasible and acceptable channels for delivery of ARV-based prevention products (oral and injectable pre-exposure prophylaxis, or PrEP, and vaginal microbicide gels) to populations at high risk of HIV infection; 2) evaluate the potential impact of such delivery on existing health services; and 3) identify the additional capacity required to support product introduction.